A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients

Julie Le Naour, Zsofia Sztupinszki, Vincent Carbonnier, Odile Casiraghi, Virginie Marty, Lorenzo Galluzzi, Zoltan Szallasi, Guido Kroemer, Erika Vacchelli

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn’s disease, and epidemiological associations between Crohn’s disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association.

Original languageEnglish
Article number2059878
JournalOncoimmunology
Volume11
Issue number1
DOIs
StatePublished - 2022
Externally publishedYes

Keywords

  • Autophagy-Related Proteins/genetics
  • Crohn Disease/genetics
  • Head and Neck Neoplasms/drug therapy
  • Humans
  • Polymorphism, Single Nucleotide
  • Squamous Cell Carcinoma of Head and Neck/drug therapy
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients'. Together they form a unique fingerprint.

Cite this